Bibliographic record
Abstract
In the Clinic3 November 2009InfluenzaChristine Laine, MD, MPH, Sankey Williams, MD, and Margaret Trexler Hessen, MDChristine Laine, MD, MPHSearch for more papers by this author, Sankey Williams, MDSearch for more papers by this author, and Margaret Trexler Hessen, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-9-200911030-01005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail With a pandemic currently in progress, influenza has maintained a prominent place in the medical and lay news cycles. The coming season promises to be challenging for clinicians, who must sort through strategies for prevention, diagnosis, and treatment for both seasonal influenza and influenza due to the novel H1N1 strain.PreventionWhat are the different types of influenza and what do we know about their cause?The 3 main types of influenza virus are A, B, and C. Influenza A is subtyped according to its main surface glycoprotein components, hemagglutinin and neuraminidase. There are at least 15 different kinds of hemagglutinin ...References1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-15. [PMID:19423869] Google Scholar2. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med. 2008;359:2579-85. [PMID:19073977] Google Scholar3. Novel H1N1 Flu Facts and Figures. Centers for Disease Control, Atlanta, GA, August 4, 2009. Accessed at www.cdc.gov/h1n1flu/surveillanceqa.htm on 10 September 2009. Google Scholar4. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58:1-52. [PMID:19644442] Google Scholar5. Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008:CD004879. [PMID:18425905] Google Scholar6. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007:CD001269. [PMID:17443504] Google Scholar7. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-32. [PMID:12672859] Google Scholar8. Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis. 2004;190:1-10. [PMID:15195237] Google Scholar9. EPIVAC Study Group. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J. 2009;30:209-16. [PMID:18997178] Google Scholar10. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350-8. [PMID:18187561] Google Scholar11. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med. 2005;165:274-80. [PMID:15710789] Google Scholar12. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-81. [PMID:17914038] Google Scholar13. Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ. 2006;333:1241. [PMID:17142257] Google Scholar14. Puck JM, Glezen WP, Frank AL, et al. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J Infect Dis. 1980;142:844-9. [PMID:7462695] Google Scholar15. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359:1555-64. [PMID:18799552] Google Scholar16. King JC Jr, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006;355:2523-32. [PMID:17167135] Google Scholar17. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000;284:1677-82. [PMID:11015798] Google Scholar18. National Center for Immunization and Respiratory Diseases, CDC. Use of influenza A (H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2009;58:1-8. Google Scholar19. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355:2513-22. [PMID:17167134] Google Scholar20. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282:137-44. [PMID:10411194] Google Scholar21. New Vaccine Surveillance Network. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics. 2008;122:911-9. [PMID:18977968] Google Scholar22. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361:1260-7. [PMID: 19776407] Google Scholar23. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007;120:e553-64. [PMID:17698577] Google Scholar24. Jefferson T, Foxlee R, Del Mar C, et al. Interventions for the interruption or reduction of the spread of respiratory viruses. Cochrane Database Syst Rev. 2007:CD006207. [PMID:17943895] Google Scholar25. World Health Organization Writing Group. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis. 2006;12:88-94. [PMID:16494723] Google Scholar26. Cowling BJ, Chan KH, Fang VJ, et al. Facemasks and hand hygiene to prevent influenza transmission in households: a randomized trial. Ann Intern Med. 2009. [PMID:19652172] Google Scholar27. Khazeni N, Bravata D, Holty JEC, et al. Safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med. 2009;151:464-73. Google Scholar28. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025-31. [PMID:11555062] Google Scholar29. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004;39:459-64. [PMID:15356805] Google Scholar30. Oseltamivir Compassionate Use Program Group. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc. 2002;50:608-16. [PMID:11982659] Google Scholar31. Ambrozaitis A, Gravenstein S, van Essen GA, et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc. 2005;6:367-74. [PMID:16286057] Google Scholar32. Rubin MS, Nivin B, Ackelsberg J. Effect of timing of amantadine chemoprophylaxis on severity of outbreaks of influenza a in adult long-term care facilities. Clin Infect Dis. 2008;47:47-52. [PMID:18484879] Google Scholar33. Trick WE, Das K, Gerard MN, et al. Clinical trial of standing-orders strategies to increase the inpatient influenza vaccination rate. Infect Control Hosp Epidemiol. 2009;30:86-8. [PMID:19046061] Google Scholar34. Zambon M, Hays J, Webster A, et al. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001;161:2116-22. [PMID:11570941] Google Scholar35. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160:3243-7. [PMID:11088084] Google Scholar36. Boivin G, Hardy I, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000;31:1166-9. [PMID:11073747] Google Scholar37. INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361:680-9. [PMID:19564631] Google Scholar38. World Health Organization. Pandemic Influenza in Pregnant Women., Geneva, Switzerland. Accessed at www.who.int/csr/disease/swineflu/notes/h1n1_pregnancy_20090731/en/index.html on 10 September 2009. Google Scholar39. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. 2007;167:354-60. [PMID:17242309] Google Scholar40. Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus - United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:826-9. [PMID:19661856] Google Scholar41. Connolly AM, Salmon RL, Lervy B, et al. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. BMJ. 1993;306:1452-4. [PMID:8518643] Google Scholar42. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-80. [PMID:9302301] Google Scholar43. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352:1877-81. [PMID:9863784] Google Scholar44. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled inhibitor zanamavir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect Dis. 2000;40:42-8 [PMID:10762110] Google Scholar45. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44 Suppl B:23-9. [PMID:10877459] Google Scholar46. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24. [PMID:10697061] Google Scholar47. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-50. [PMID:10866439] Google Scholar48. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303-13. [PMID:16443037] Google Scholar49. Jefferson TO, Demicheli V, Di Pietrantonj C, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2006;3:CD001265. [PMID:16855962] Google Scholar50. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235. [PMID:12791735] Google Scholar51. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161:212-7. [PMID:11176734] Google Scholar52. Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568-75. [PMID:18190317] Google Scholar53. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther. 2007;12:501-8. [PMID:17668558] Google Scholar54. Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003-32. [PMID:19281331] Google Scholar55. Centers for Disease Control and Prevention. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season. Accessed at www.cdc.gov/h1n1flu/recommendations.htm on 10 September 2009. Google Scholar56. CMS Medicare and Medicaid programs: condition of participation: immunization standard for long-term care facilities. Final rule. Fed Regist 2005;70:58833-52 Google Scholar57. Physician Quality and Reporting Initiative. 2009 PQRI Quality Measures List. Accessed at www.cms.hhs.gov/PQRI/Downloads/2009_PQRI_MeasuresList_030409.pdf on 10 September 2009 Google Scholar58. The Joint Commission. Accessed at www.jointcommission.org on 10 September 2009. Google Scholar Author, Article, and Disclosure InformationAuthors: Christine Laine, MD, MPH; Sankey Williams, MD; Margaret Trexler Hessen, MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAbdominal Aortic AneurysmAbdominal Aortic Aneurysm 3 November 2009Volume 151, Issue 9 Page: ITC5-1 Keywords Child health Children Fevers H1N1 Health care Infectious diseases Nursing homes Pregnancy Prophylaxis Vaccines ePublished: 3 November 2009 Issue Published: 3 November 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.003 | 0.001 |
| Open science | 0.001 | 0.002 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.476 | 0.392 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".